Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials

Gynecologic Oncology

Volumn 106, Issue 3, 2007, Pages 469-475

  Harrison, Michelle L ^a   Gore, Martin E ^a   Spriggs, David ^b   Kaye, Stan ^a   Iasonos, Alexia ^b   Hensley, Martee ^b   Aghajanian, Carol ^b   Venkatraman, Ennapadam ^b   Sabbatini, Paul ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Consolidation trials; Ovarian cancer; Remission duration

Indexed keywords

PLATINUM; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE DURATION; FEMALE; HUMAN; MAINTENANCE THERAPY; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 34548120869     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.05.008     Document Type: Article

References (29)

1. Dizon D.S., Hensley M.L., Poynor E.A., Sabbatini P., Aghajanian C., Hummer A., et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J. Clin. Oncol. 20 (2002) 1238-1247
2. Dizon D.S., Dupont J., Anderson S., Sabbatini P., Hummer A., Arghajanian C., et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecol. Oncol. 91 (2003) 584-590
3. du Bois A., Weber B., Rochon J., Meier W., Goupil A., Olbricht S., et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J. Clin. Oncol. 24 (2006) 1127-1135
4. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
5. Harries M., and Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 3 (2002) 537-545
6. Harries M., and Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 3 (2002) 529-536
7. Markman M. Viewing ovarian cancer as a "chronic disease": what exactly does this mean?. Gynecol. Oncol. 100 (2006) 229-230
8. Sabbatini P., and Spriggs D.R. Consolidation for ovarian cancer in remission. J. Clin. Oncol. 24 (2006) 537-539
9. Pfisterer J., Weber B., Reuss A., Kimmig R., du Bois A., Wagner U., et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J. Natl. Cancer Inst. 98 (2006) 1036-1045
10. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
11. Markman M., Markman J., Webster K., Zanotti K., Kulp B., Peterson G., et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J. Clin. Oncol. 22 (2004) 3120-3125
12. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J., et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19 (2001) 3312-3322
13. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
14. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24 (2006) 4699-4707
15. Gronlund B., Hogdall C., Christensen I.J., Engelholm S.A., and Hansen H.H. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with paclitaxel-platinum?. Gynecol. Oncol. 94 (2004) 409-415
16. Polverino G., Parazzini F., Stellato G., Scarfone G., Cipriani S., and Bolis G. Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy. Gynecol. Oncol. 99 (2005) 343-347
17. Voest E.E., van Houwelingen J.C., and Neijt J.P. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log [relative risk] as main objectives). Eur. J. Cancer Clin. Oncol. 25 (1989) 711-720
18. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., et al. Second line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9 (1991) 389-393
19. ten Bokkel Huinik W., Gore M., Carmicheal J., Gordon A., Malfetano J., Hudson I., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15 (1997) 2183-2193
20. Markman M., and Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J. Clin. Oncol. 10 (1992) 513-514
21. Rustin G.J., Timmers P., Nelstrop A., Shreeves G., Bentzen S.M., Baron B., et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J. Clin. Oncol. 24 (2006) 45-51
22. Rustin G.J., Nelstrop A.E., and Tuxen M.K. Defining progression of ovarian carcinoma during followup according to CA 125: a North Thames Ovary Group Study. Ann. Oncol. 7 (1996) 361-364
23. Gronlund B., Hansen H.H., Hogdall C., Hogdall E.V., and Engelholm S.A. Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?. Br. J. Cancer 90 (2004) 377-382
24. Gronlund B., Hogdall C., Hilden J., Engelholm S.A., Hogdall E.V., and Hansen H.H. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?. J. Clin. Oncol. 22 (2004) 4051-4058
25. Roland P.Y., Barnes M.N., Niwas S., Robertson M.W., Alvarez R., Austin J.M., et al. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens. Gynecol. Oncol. 68 (1998) 178-182
26. Ferrero M., Weber B., Geay J.F., Lepille D., Orfeuvre H., Combe M., et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann. Oncol. 18 (2006) 263-268
27. Piver M.S., Lele S.B., Marchetti D.L., Baker T.R., Tsukada Y., and Emrich L.J. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J. Clin. Oncol. 6 (1988) 983-989
28. Hoskins P., Tu D., James K., Pater J., and Koski B. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups. Gynecol. Oncol. 70 (1998) 224-230
29. Eisenhauer E.A., Vermorken J.B., and van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]. Ann. Oncol. 8 (1997) 963-968